Literature DB >> 15237895

Methicillin-resistant staphylococcal infections: an important consideration for orthopedic surgeons.

Wael E Shams1, Robert P Rapp.   

Abstract

Postoperative infections in joint prostheses and fracture-fixation devices commonly involve both MRSA and methicillin resistant coagulase-negative staphylococcus. In addition, community-acquired MRSA has also become an important consideration when infected patients are admitted to the hospital from the community. Preoperative colonization with MRSA and methicillin resistant coagulase-negative staphylococcus increases the risk of postoperative surgical site infections in orthopedic patients. Up to 5.3% of orthopedic patients are colonized with these organisms on hospital admission. Screening and decolonization of methicillin resistant staphylococci decrease the incidence of postoperative surgical site infections in the orthopedic patient. This may be particularly important in orthopedic implants given the difficulty encountered in treating infected prosthesis. Current US guidelines advocate screening for methicillin resistant staphylococci only when risk factors are present. Growing evidence suggests that screening and decolinization of all patients having elective orthopedic procedures, especially those including prosthetic implants, will decrease the incidence of postoperative infections. The infected prosthesis may be potentially salvaged if the clinical manifestations of infection have been present for < or = 10 days, the implant is stable, and the etiologic organisms are susceptible to oral antibiotics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15237895     DOI: 10.3928/0147-7447-20040601-12

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  9 in total

1.  Two-stage total hip arthroplasty: how often does it control methicillin-resistant infection?

Authors:  Fay Leung; Corey J Richards; Donald S Garbuz; Bassam A Masri; Clive P Duncan
Journal:  Clin Orthop Relat Res       Date:  2011-04       Impact factor: 4.176

2.  Molecular fingerprinting of Staphylococcus aureus isolated from patients with osteomyelitis in Argentina and clonal distribution of the cap5(8) genes and of other selected virulence genes.

Authors:  S M Lattar; L P N Tuchscherr; D Centrón; K Becker; S C Predari; F R Buzzola; D A Robinson; D O Sordelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-27       Impact factor: 3.267

3.  Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.

Authors:  Daniela Baldoni; Manuel Haschke; Zarko Rajacic; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  Implementing the MRSA recommendations made by the Commission for Hospital Hygiene and Infection Prevention (KRINKO) of 1999 - current considerations by the DGKH Management Board.

Authors:  Arne Simon; Martin Exner; Axel Kramer; Steffen Engelhart
Journal:  GMS Krankenhhyg Interdiszip       Date:  2009-04-09

5.  Capsule expression and genotypic differences among Staphylococcus aureus isolates from patients with chronic or acute osteomyelitis.

Authors:  Santiago M Lattar; Lorena P N Tuchscherr; Roberto L Caccuri; Daniela Centrón; Karsten Becker; Claudio A Alonso; Claudia Barberis; Graciela Miranda; Fernanda R Buzzola; Christof von Eiff; Daniel O Sordelli
Journal:  Infect Immun       Date:  2009-03-09       Impact factor: 3.441

6.  Cis-2-decenoic acid inhibits S. aureus growth and biofilm in vitro: a pilot study.

Authors:  Jessica Amber Jennings; Harry S Courtney; Warren O Haggard
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

7.  MRSA in a large German University Hospital: Male gender is a significant risk factor for MRSA acquisition.

Authors:  Markus Kupfer; Lutz Jatzwauk; Stephan Monecke; Jana Möbius; Axel Weusten
Journal:  GMS Krankenhhyg Interdiszip       Date:  2010-09-21

8.  Postoperative Staphylococcus aureus infections in Medicare beneficiaries.

Authors:  Moaven Razavi; Donald S Shepard; Jose A Suaya; William B Stason
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

9.  Toxic shock syndrome toxin-1-mediated toxicity inhibited by neutralizing antibodies late in the course of continual in vivo and in vitro exposure.

Authors:  Norbert Stich; Nina Model; Aysen Samstag; Corina S Gruener; Hermann M Wolf; Martha M Eibl
Journal:  Toxins (Basel)       Date:  2014-05-30       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.